FDA approval timelines have become a significant organizing principle for a cohort of healthcare-focused hedge funds that track regulatory calendars as investment catalysts. Armistice Capital, which manages more than $7 billion and maintains concentrated positions in biopharma, is among the funds that have built portfolios around companies with defined near-term […]